… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… and proprietary next generation RNA editing technology, Axiomer®, that utilizes endogenous RNA editing processes to … programs and our broader RNA technologies, including the Axiomer® RNA editing platform that was recently introduced at …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini